The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial
Open accessAbstract
OBJECTIVE: To investigate the long term effect of hormone replacement therapy on cardiovascular outcomes in recently postmenopausal women. DESIGN: Open label, randomised controlled trial. SETTING: Denmark, 1990-93. PARTICIPANTS: 1006 healthy women aged 45-58 who were recently postmenopausal or had perimenopausal symptoms in combination with recorded postmenopausal serum follicle stimulating hormone values. 502 women were randomly allocated to receive hormone replacement therapy and 504 to receive no treatment (control). Women who had undergone hysterectomy were included if they were aged 45-52 and had recorded values for postmenopausal serum follicle stimulating hormone. INTERVENTIONS: In the treatment group, women with an intact uterus were treated with triphasic estradiol and norethisterone acetate and women who had undergone hysterectomy received 2 mg estradiol a day. Intervention was stopped after about 11 years owing to adverse reports from other trials, but participants were followed for death, cardiovascular disease, and cancer for up to 16 years. Sensitivity analyses were carried out on women who took more than 80% of the prescribed treatment for five years. MAIN OUTCOME MEASURE: The primary endpoint was a composite of death, admission to hospital for heart failure, and myocardial infarction. RESULTS: At inclusion the women on average were aged 50 and had been postmenopausal for seven months. After 10 years of intervention, 16 women in the treatment group experienced the primary composite endpoint compared with 33 in the control group (hazard ratio 0.48, 95% confidence interval 0.26 to 0.87; P=0.015) and 15 died compared with 26 (0.57, 0.30 to 1.08; P=0.084). The reduction in cardiovascular events was not associated with an increase in any cancer (36 in treated group v 39 in control group, 0.92, 0.58 to 1.45; P=0.71) or in breast cancer (10 in treated group v 17 in control group, 0.58, 0.27 to 1.27; P=0.17). The hazard ratio for deep vein thrombosis (2 in treated group v 1 in control group) was 2.01 (0.18 to 22.16) and for stroke (11 in treated group v 14 in control group) was 0.77 (0.35 to 1.70). After 16 years the reduction in the primary composite outcome was still present and not associated with an increase in any cancer. CONCLUSIONS: After 10 years of randomised treatment, women receiving hormone replacement therapy early after menopause had a significantly reduced risk of mortality, heart failure, or myocardial infarction, without any apparent increase in risk of cancer, venous thromboembolism, or stroke. TRIAL REGISTRATION: ClinicalTrials.gov NCT00252408.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Writing Group for the Women's Health Initiative Investigators (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.3.321 · Cited by 15,889
Hulley, S. (1998) · JAMA · doi:10.1001/jama.280.7.605 · Cited by 6,216
Valery (1995) · doi:10.1001/jama.1995.03520270033028 · Cited by 2,320
The Danish National Hospital Register. A valuable source of data for modern health sciences.
Andersen, T. F., Madsen, M., Jørgensen, J. O. L., Mellemkjoer, L., & Olsen, J. H. (1999) · PubMed · Cited by 2,026
Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause
Rossouw, J. E., Prentice, R. L., Manson, J. E., Wu, L., Barad, D., Barnabei, V. M., Ko, M., LaCroix, A. Z., Margolis, K. L., & Stefanick, M. L. (2007) · JAMA · doi:10.1001/jama.297.13.1465 · Cited by 1,741
Postmenopausal Estrogen and Progestin Use and the Risk of Cardiovascular Disease
Grodstein, F., Stampfer, M. J., Manson, J. E., Colditz, G. A., Willett, W. C., Rosner, B., Speizer, F. E., & Hennekens, C. H. (1996) · New England Journal of Medicine · doi:10.1056/nejm199608153350701 · Cited by 1,305
Postmenopausal Hormone Replacement Therapy: Scientific Review
Nelson, H. D., Humphrey, L. L., Nygren, P., Teutsch, S. M., & Allan, J. D. (2002) · JAMA · doi:10.1001/jama.288.7.872 · Cited by 990
Pharmacology of estrogens and progestogens: influence of different routes of administration
Kuhl, H. (2005) · Climacteric · doi:10.1080/13697130500148875 · Cited by 835
Estrogen in the Prevention of Atherosclerosis: A Randomized, Double-Blind, Placebo-Controlled Trial
Hodis, H. N., Mack, W. J., Lobo, R. A., Shoupe, D., Sevanian, A., Mahrer, P. R., Selzer, R. H., Liu, C.-R., Liu, C.-H., Azen, S. P., et al. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-135-11-200112040-00005 · Cited by 687
Conjugated Equine Estrogens and Coronary Heart Disease: The Women's Health Initiative
Hsia, J. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.3.357 · Cited by 610
Cited by
2013 ESC guidelines on the management of stable coronary artery disease
Task Force Members, Montalescot, G., Sechtem, U., Achenbach, S., Andreotti, F., Arden, C., Budaj, A., Bugiardini, R., Crea, F., Cuisset, T., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht296 · Cited by 4,510
El Khoudary, S. R., Aggarwal, B., Beckie, T. M., Hodis, H. N., Johnson, A. E., Langer, R. D., Limacher, M. C., Manson, J. E., Stefanick, M. L., Allison, M. A., et al. (2020) · Circulation · doi:10.1161/cir.0000000000000912 · Cited by 1,219
Cardiovascular Risks Associated with Gender and Aging
Rodgers, J. L., Jones, J., Bolleddu, S. I., Vanthenapalli, S., Rodgers, L. E., Shah, K., Karia, K., & Panguluri, S. K. (2019) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd6020019 · Cited by 1,024
The 2017 hormone therapy position statement of The North American Menopause Society
(2017) · Menopause · doi:10.1097/gme.0000000000000921 · Cited by 1,001
The 2022 hormone therapy position statement of The North American Menopause Society
(2022) · Menopause · doi:10.1097/gme.0000000000002028 · Cited by 977
2016 IMS Recommendations on women’s midlife health and menopause hormone therapy
Baber, R. J., Panay, N., & Fenton, A. (2016) · Climacteric · doi:10.3109/13697137.2015.1129166 · Cited by 964
Bushnell, C., McCullough, L. D., Awad, I. A., Chireau, M. V., Fedder, W. N., Furie, K. L., Howard, V. J., Lichtman, J. H., Lisabeth, L. D., Piña, I. L., et al. (2014) · Stroke · doi:10.1161/01.str.0000442009.06663.48 · Cited by 941
Iorga, A., Cunningham, C. M., Moazeni, S., Ruffenach, G., Umar, S., & Eghbali, M. (2017) · Biology of Sex Differences · doi:10.1186/s13293-017-0152-8 · Cited by 914
Treatment of symptoms of the menopause: an Endocrine Society Clinical Practice Guideline
Stuenkel, C. A., Davis, S. R., Gompel, A., Lumsden, M. A., Murad, M. H., Pinkerton, J. V., & Santen, R. J. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2236 · Cited by 884
Vascular effects of early versus late postmenopausal treatment with estradiol
Hodis, H. N., Mack, W. J., Henderson, V. W., Shoupe, D., Budoff, M. J., Hwang-Levine, J., Li, Y., Feng, M., Dustin, L., Kono, N., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1505241 · Cited by 779
Hormone therapy for preventing cardiovascular disease in post-menopausal women
Boardman, H. M., Hartley, L., Eisinga, A., Main, C., Roqué i Figuls, M., Bonfill Cosp, X., Gabriel Sanchez, R., & Knight, B. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002229.pub4 · Cited by 612
Long term hormone therapy for perimenopausal and postmenopausal women
Farquhar, C., Marjoribanks, J., Lethaby, A., Suckling, J. A., & Lamberts, Q. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004143.pub2 · Cited by 582
Sex-specific differences in hypertension and associated cardiovascular disease
Colafella, K. M. M., & Denton, K. M. (2018) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.189 · Cited by 490
Hormone-replacement therapy: current thinking
Lobo, R. A. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.164 · Cited by 484
Primary osteoporosis in postmenopausal women
Ji, M., & Yu, Q. (2015) · Chronic Diseases and Translational Medicine · doi:10.1016/j.cdtm.2015.02.006 · Cited by 436
Long-term hormone therapy for perimenopausal and postmenopausal women
Marjoribanks, J., Farquhar, C., Roberts, H., Lethaby, A., & Lee, J. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004143.pub5 · Cited by 424
Hankey, G. J. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70255-2 · Cited by 384
Maas, A. H. E. M., Rosano, G., Cifkova, R., Chieffo, A., van Dijken, D., Hamoda, H., Kunadian, V., Laan, E., Lambrinoudaki, I., Maclaran, K., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehaa1044 · Cited by 344
Comprehensive review of cardiovascular toxicity of drugs and related agents
Mladěnka, P., Applová, L., Patočka, J., Costa, V. M., Remiao, F., Pourová, J., Mladěnka, A., Karlíčková, J., Jahodář, L., Vopršalová, M., et al. (2018) · Medicinal Research Reviews · doi:10.1002/med.21476 · Cited by 310
The Controversial History of Hormone Replacement Therapy
Cagnacci, A., & Venier, M. (2019) · Medicina · doi:10.3390/medicina55090602 · Cited by 298
The clinical consequences of an ageing world and preventive strategies
Lunenfeld, B., & Stratton, P. (2013) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2013.02.005 · Cited by 285
Prevention of diseases after menopause
Lobo, R. A., Davis, S. R., De Villiers, T. J., Gompel, A., Henderson, V. W., Hodis, H. N., Lumsden, M. A., Mack, W. J., Shapiro, S., & Baber, R. J. (2014) · Climacteric · doi:10.3109/13697137.2014.933411 · Cited by 279
Menopausal hormone therapy for the management of osteoporosis
Gosset, A., Pouillès, J.-M., & Trémollieres, F. (2021) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2021.101551 · Cited by 193
Hamoda, H., Panay, N., Pedder, H., Arya, R., & Savvas, M. (2020) · Post Reproductive Health · doi:10.1177/2053369120957514 · Cited by 192
Obesity in menopause - our negligence or an unfortunate inevitability
Kozakowski, J., Gietka-Czernel, M., Leszczyńska, D., & Majos, A. (2017) · Menopausal Review · doi:10.5114/pm.2017.68594 · Cited by 189
Hormone replacement therapy – Current recommendations
Vigneswaran, K., & Hamoda, H. (2022) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2021.12.001 · Cited by 151
Is there a role for menopausal hormone therapy in the management of postmenopausal osteoporosis?
Rozenberg, S., Al-Daghri, N., Aubertin-Leheudre, M., Brandi, M.-L., Cano, A., Collins, P., Cooper, C., Genazzani, A. R., Hillard, T., Kanis, J. A., et al. (2020) · Osteoporosis International · doi:10.1007/s00198-020-05497-8 · Cited by 149
Unraveling female reproductive senescence to enhance healthy longevity
Dong, L., Teh, D. B. L., Kennedy, B. K., & Huang, Z. (2023) · Cell Research · doi:10.1038/s41422-022-00718-7 · Cited by 101
Regulatory Actions of Estrogen Receptor Signaling in the Cardiovascular System
Ueda, K., Adachi, Y., Liu, P., Fukuma, N., & Takimoto, E. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00909 · Cited by 60
Roehm, E. (2015) · Obstetrics and Gynecology International · doi:10.1155/2015/713295 · Cited by 22
Reproductive factors in relation to heart failure in women: A systematic review
Bolijn, R., Onland-Moret, N. C., Asselbergs, F. W., & van der Schouw, Y. T. (2017) · Maturitas · doi:10.1016/j.maturitas.2017.09.004 · Cited by 17
Metadata
- Authors
- Schierbeck, L. L., Rejnmark, L., Tofteng, C. L., Stilgren, L., Eiken, P., Mosekilde, L., Kober, L., & Jensen, J.-E. B.
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 2012-10-09
- Volume
- 345
- Issue
- oct09 2
- Pages
- e6409-e6409
- ISSN
- 1756-1833 (ISSN-L)
- OpenAlex
- W2089358310
- Cited by
- 747
- References
- 43
- FWCI
- 55.46
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.